|
CMS has policies that effect the use of Erythropoietin Stimulating Agents in ESRD facilities. To find out more, click on the links below.
| Downloads | ESA Monitoring Policy, Effective October 1, 2006 [PDF, 151 KB] ESA Monitoring Policy, Effective April 1, 2006 [PDF, 173 KB] Medicare Benefit Policy Manual, Chapter 11, End Stage Renal Disease (ESRD) - Section 90 – Epoetin (EPO) [PDF, 347KB] Medicare Claims Processing Manual, Chapter 8 – Outpatient ESRD Hospital, Independent Facility and Physician/Supplier Claims - Section 60.4 – Epoetin Alfa (EPO) and Section 60.7 – Darbepoetin Alfa (Aranesp) for ESRD Patients [PDF, 625KB]
| | Related Links Inside CMS | ESA Monitoring Policy, Effective January 1, 2008
NCD for ESAs for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on Dialysis - CAG-00413N
NCD for ESAs for Cancer and Related Neoplastic Conditions - CAG-00383N
Coverage Center
Medicare Coverage Database | | Related Links Outside CMS |  |
There are no Related Links Outside CMS
|
Page Last Modified: 11/29/2011 12:37:20 PM
Help with File Formats and Plug-Ins
Submit Feedback
|
